AHASTAT blog: Reducing 340B is not the answer to curbing skyrocketing drug prices

Mar 08, 2016 - 04:28 PM

A recent proposal that calls for reducing the benefits of the 340B Drug Pricing Program to curb rapidly rising prescription drug costs is “misguided,” writes AHA Executive Vice President Tom Nickels in an AHASTAT blog post today. Responding to a recent opinion piece in the New England Journal of Medicine, Nickels said, “The 340B program is more important now than ever before as the prices of prescription drugs continue to skyrocket. Instead of trying to make changes to a program with a strong track record of increasing access to care for patients in vulnerable communities, policymakers should consider other solutions, such as requiring greater transparency on drug pricing and charity policies by drug companies, increased competition in the generic industry or other reasonable proposals.” For more on the 340B program, visit www.aha.org/protect340B.

Related News Articles

Headline
Appeals court upholds lower court denial of AbbVie’s preliminary injunction, preserving Mississippi 340B contract pharmacy law
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction…
Perspective
Hospital Outpatient Departments Are Different from Independent Physician Offices
Public
Every health care provider strives to deliver their patients the best possible care, but not all providers offer the same level or complexity of care. Current…
Headline
Study: MA beneficiaries’ hospital stays longer than those under Traditional Medicare
A JAMA internal medicine study published Sept. 8 found that since the COVID-19 pandemic, Medicare Advantage beneficiaries have been experiencing longer…
Headline
AHA urges FTC, DOJ to investigate anticompetitive activity by drug companies on 340B rebate models 
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…
Headline
Study finds less than 40% of Medicare beneficiaries with OUD receive standard care
A Health Affairs study published Sept. 2 found that less than 40% of Medicare beneficiaries with opioid use disorder received standard care in alignment with…
Headline
AHA study finds HOPDs treat sicker patients than independent physician offices
The AHA Sept. 3 released a study conducted by KNG Health Consulting that found Medicare patients who receive care in a hospital outpatient department are more…